Clemastine for lesion repair in relapsing-remitting multiple sclerosis
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests whether a medication called clemastine fumarate (an antihistamine) can help repair the protective coating around nerves in people with relapsing-remitting multiple sclerosis. Researchers will use MRI scans to see if the drug improves lesion healing over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have relapsing-remitting multiple sclerosis and have had the disease for less than 15 years.
- You need to be between 18 and 55 years old.
- If you are a woman who could become pregnant, you must agree to use effective birth control during the trial.
- Your most recent MRI (within the last 3 months) must not show a new or active brain lesion.
- You cannot have taken steroids (like prednisone) in the 30 days before starting.
- You must be able to undergo MRI scans without metal in your body (like braces) that could interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether clemastine (a drug being studied for “myelin repair”) changes how MS looks on special MRI scans. It may help researchers understand if the treatment supports restoring nerve covering in people with relapsing-remitting MS.
This Phase 2 trial tests whether clemastine can help regrow the protective covering around the optic nerve after acute optic neuritis (an inflammation-related vision problem). It may help improve vision recovery and signal how well “remyelination” happens.
This study tests whether N-acetyl cysteine (a supplement-like medicine) changes body and brain function in people with multiple sclerosis. It may help researchers understand how it affects brain chemistry and activity using special brain imaging.
This trial tests a device that stimulates a nerve in the neck, which may help repair the protective coating around nerves in the brain and spinal cord. It is for people with relapsing-remitting MS who are stable on their current medication and have some vision problems due to MS.
This study tests an oral medication, dimethyl fumarate, which is already used for multiple sclerosis. It aims to see how well it controls relapses in people with relapsing forms of MS. If you have had a relapse in the last year, you might be eligible.
This trial tests whether cladribine (vs an inactive placebo pill) can slow disability worsening in people with a non-active, progressive form of multiple sclerosis. It may help by reducing the immune activity that can drive ongoing nerve damage, even without recent relapses.
Hear when a new Demyelinating Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.